Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

325 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-04-30

Study Completion Date

2000-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study the effect of etoricoxib 60 mg and 90 mg compared to placebo to treat chronic low back pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-042)

NCT00393211

Recurrent Low Back Pain

COMPLETED PHASE3

Study of MK0663 in Patients With Chronic Low Back Pain (0663-806)(COMPLETED)

NCT00090181

Chronic Low Back Pain

COMPLETED PHASE4

Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)

NCT00757627

Pain

COMPLETED PHASE4

Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)

NCT00242489

Osteoarthritis

COMPLETED PHASE2

An Investigational Drug in Patients With Osteoarthritis (0663-073)

NCT00092755

Osteoarthritis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Low Back Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK0663, Etoricoxib / Duration of Treatment : 12 Weeks

Intervention Type DRUG

Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Low back pain for previous 3 months and majority of days in last month
* Regular use of acetaminophen or NSAID to treat low back pain in past month
* Judged to be in otherwise good health

Exclusion Criteria

* Low back pain that is due to secondary causes
* Radicular/myelopathic pain
* Surgery for low back pain within the past 6 months
* Active lawsuit or claim pertaining to their low back pain
* Disease that may confound the results of the study or pose risk to the patients
* Corticosteroid use in past month
* Previous participation in MK0663 study

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No